1. INTRODUCTION
===============

Several investigation suggest that abnormalities in circadian rhythms may be involved in the pathophysiology of psychiatric disorders, including drug addiction \[[@R1]-[@R3]\]. The evidence for this relation is discussed in more detail in our previous papers and a review by Barnard and Nolan \[[@R4]-[@R7]\].

Recently, Mohawk and colleagues reported that mice which were arrhythmic due to a lack of circadian clock genes showed circadian locomotor rhythms when treated with methamphetamine \[[@R8]\]. If patients with drug addiction disorders had disrupted circadian rhythms, it is possible that taking methamphetamine helps to restore circadian rhythms of taking into methamphetamine to keep to circadian rhythm. Several animal studies have shown that methamphetamine increased expression of circadian clock molecule genes such as *Per1*, *Per2*, *Bmal1*, and *Npas2*in the brain \[[@R9]-[@R11]\]. Recently, we detected the significant association between prokineticin 2 receptor gene (*PROKR2*), which is one of the clock genes, and Japanese methamphetamine dependence patients \[[@R12]\].

Recently, rev-erb alpha and glycogen synthase kinase-3 β (GSK-3β), which are known to be important circadian components \[[@R13]\], have been discussed in relation with lithium. Several studies have revealed that lithium affects circadian rhythms through GSK-3β \[[@R14]-[@R16]\]. Yin *et al.* showed that Rev-erb alpha is a target of GSK-3β kinase activity, needed to mediate this effect to regulate circadian rhythms \[[@R13]\]. These evidences indicate that rev-erb alpha gene (*NR1D1*) is a good candidate gene for the pathogenesis of methamphetamine dependence.

To evaluate the association between *NR1D1* and methamphetamine dependence, we conducted a case-control study of Japanese samples (215 methamphetamine dependence and 232 controls) with three tagging SNPs selected by HapMap database.

2. MATERIALS AND METHODS
========================

2.1. Subjects
-------------

The subjects in the association analysis were 215 METH deprendence patients (175 males and 40 females; mean age ± standard deviation (SD) 36.3 ± 11.4 years) and 232 healthy controls (187 males and 45 females; 36.4 ± 11.3 years). The age and sex of the control subjects did not differ from those of the methamphetamine dependence patients. All subjects were unrelated to each other, ethnically Japanese, and lived in the central area of Japan. The patients were diagnosed according to DSM-IV criteria with consensus of at least two experienced psychiatrists on the basis of unstructured interviews and a review of medical records. One hundred ninety-seven of the subjects with METH dependence had a diagnosis of co-morbid METH induced psychosis. METH-induced psychosis patients were divided into two categories of psychosis prognosis, the transient type and the prolonged type, which showed remission of psychotic symptoms within 1 month and after more than 1 month, respectively, after the discontinuance of methamphetamine consumption and beginning of treatment with neuroleptics; 112 patients (56.9%) were the transient type, and 85 patients (42.1%) were the prolonged type. One hundred eighty-two subjects with METH-induced psychosis also had dependence on drugs other than METH. Cannabinoids were the most frequency abused drugs (21.4%), followed by cocaine (9.09%), LSD (9.09%), opioids (7.69%), and hypnotics (7.69%). Subjects with METH-induced psychosis were excluded if they had a clinical diagnosis of psychotic disorder, mood disorder, anxiety disorder or eating disorder. More detailed characterizations of these subjects have been published elsewhere \[[@R17],[@R18]\]. All healthy controls were also psychiatrically screened based on unstructured interviews. None had severe medical complications such as liver cirrhosis, renal failure, heart failure or other Axis-I disorders according to DSM-IV.

The study was described to subjects and written informed consent was obtained from each. This study was approved by the Ethics Committee at Fujita Health University, Nagoya University School of Medicine and and each participating member of the Institute of the Japanese Genetics Initiative for Drug Abuse (JGIDA).

2.2. SNPs Selection and Linkage Disequilibrium (LD) Evaluation
--------------------------------------------------------------

We first consulted the HapMap database (release\#20/phase II, Jan 2006, [www.hapmap.org](www.hapmap.org), population: Japanese Tokyo, minor allele frequencies (MAFs) of more than 0.05) and included 5 SNPs covering *NR1D1* (5'-flanking regions including about 750 bp from the initial exon and about 1 kb downstream (3') from the last exon: HapMap database contig number chr17: 35501880..35510616). Then three 'tagging (tag) SNPs' were selected with the criteria of r^2^ threshold greater than 0.8 in 'pair-wise tagging only' mode using the 'Tagger' program (Paul de Bakker, <http://www/broad.mit.edu/mpg/tagger>), in Haploview \[[@R19]\], three 'tag SNPs' (rs939347, rs2071427 and rs3744805) were selected for the following association analysis.

2.3. SNPs Genotyping
--------------------

We used TaqMan assays (ABI: Applied Biosystems, Inc., Foster City, CA,) for all SNPs. One allelic probe was labeled with FAM dye and the other with the fluorescent VIC dye. The plates were heated for 2 min at 50°C and 95°C for 10 min, followed by 45 cycles of 95°C for 15 s and 58°C for 1 min. Please refer to ABI for the primer sequence. Detailed information is available on request.

2.4. Statistical Analysis
-------------------------

Genotype deviation from the Hardy-Weinberg equilibrium (HWE) was evaluated by chi-square test (SAS/Genetics, release 8.2, SAS Japan Inc, Tokyo, Japan).

Marker-trait association analysis was used to evaluate allele- and genotype-wise association with the chi-square test (SAS/Genetics, release 8.2, SAS Japan Inc, Tokyo, Japan), and haplotype-wise association analysis was conducted with a likelihood ratio test using the COCAPHASE2.402 program \[[@R20]\]. We used the permutation test option as provided in the haplotype-wise analysis to avoid spurious results and correct for multiple testing. Permutation test correction was performed using 1000 iterations (random permutations). Power calculation was performed using a genetic power calculator \[[@R21]\]. The significance level for all statistical tests was 0.05.

3. RESULTS
==========

The LD structure of *NR1D1* from the HapMap database samples can be seen our previous paper \[[@R22]\]. Genotype frequencies of all SNPs were in HWE. We did not detect between all tagging SNPs and METH dependence in the Japanese population in the allele /genotype-wise (Table **[1](#T1){ref-type="table"}**) or haplotype-wise analysis (*P* ~haplotype~= 0.775). In addition, we found no association between four tagging SNPs and METH-induced psychosis patients in the allele /genotype-wise (Table **[1](#T1){ref-type="table"}**) or haplotype-wise analysis (*P* ~haplotype~= 0.699).

In the power analysis, we obtained more than 80% power for the detection of association when we set the genotype relative risk at 1.63-1.86 in METH dependence for *NR1D1*under a multiplicative model of inheritance

4. DISCUSSION
=============

We did not find an association between *NR1D1* and Japanese METH dependence and METH-induced psychosis patients. Therefore, we reasoned that *NR1D1* may not play an important role in the pathophysiology of METH dependence and METH-induced psychosis in the Japanese population. However, because our samples are small, we considered that there is a possibility of statistical error in these results.

Recently, we reported that *NR1D1* was not associated with major depressive disorder and selective serotonin reuptake inhibitor response to major depressive disorder \[[@R7],[@R22]\]. On the other hand, we detected the associations between *PROKR2* and not only mood disorders including major depressive disorder and bipolar disorder but also METH dependence and METH-induced psychosis in the Japanese population \[[@R12],[@R23]\]. We hypothesized that mood disorders and drug addiction have common susceptibility genes.

A few points of caution should be mentioned with respect to our results. Firstly, the lack of association may be due to small sample size. Ideal samples for this study are METH use disorder samples with and without dependence and psychosis. Because we had only a few METH use disorder samples without dependence and psychosis, and we wanted to avoid statistical error, we did not perform an association analysis with these samples. Secondly, we did not include a mutation scan to detect rare variants. We designed the study based on the common disease-common variants hypothesis \[[@R24]\]. Further investigation will be required, such as medical resequencing using larger samples. However, statistical power is needed to evaluate the association of rare variants. To overcome these limitations, a replication study using larger samples or samples of other populations will be required for conclusive results \[[@R25]\].

In conclusion, our results suggest that *NR1D1* may not play a role in the pathophysiology of METH dependence in the Japanese population. However, because we did not perform a mutation scan of*NR1D1*, a replication study using a larger sample may be required for conclusive results.
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Association Analysis of *NRIDI* with Methamphetamine Dependence and Methamphetamine-Induced Psychosis

  SNP ID[a](#T1F1){ref-type="table-fn"}   Phenotype[b](#T1F2){ref-type="table-fn"}   MAF[c](#T1F3){ref-type="table-fn"}   N     Genotype Distribution[d](#T1F4){ref-type="table-fn"}   P-Value[e](#T1F5){ref-type="table-fn"}                         
  --------------------------------------- ------------------------------------------ ------------------------------------ ----- ------------------------------------------------------ ---------------------------------------- ----- ------- ------- -------
  rs939347                                Control                                    0.483                                232   59                                                     121                                      52    0.502           
  A\>G                                    METH dependence                            0.498                                215   55                                                     106                                      232   0.838   0.770   0.703
                                          METH-induced psychosis                     0.487                                197   51                                                     100                                      46    0.824   0.956   0.944
  rs2071427                               Control                                    0.469                                232   66                                                     114                                      52    0.835           
  G\>A                                    METH dependence                            0.458                                215   65                                                     103                                      47    0.470   0.918   0.726
                                          METH-induced psychosis                     0.452                                197   59                                                     98                                       40    0.952   0.856   0.597
  rs3744805                               Control                                    0.489                                232   62                                                     113                                      57    0.699           
  A\>G                                    METH dependence                            0.516                                215   51                                                     106                                      58    0.850   0.720   0.419
                                          METH-induced psychosis                     0.518                                197   49                                                     92                                       56    0.363   0.659   0.405

major allele\>minor allele

METH: methamphetamin

MAF: minor allele frequency

M: major allele, m: minor allele

Hardy-Weinberg equilibrium
